drugset
drugset / Trial / NCT04520321

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT04520321 ↗

Phase 1/2 Completed 22 enrolled Trefoil Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study

Timeline

Start
2020-08-19
Primary completion
2021-04-23
Completion
2021-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject TTHX1114 Protein / enzyme biologic — Other

Indications

Fuchs' endothelial dystrophy bullous keratopathy